Skip to main content

Table 1 Patient characteristics

From: Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer

 

HER2-positive (n = 12), number of patients (%)

HER2-negative (n = 4), number of patients (%)

Median age

61

66

ER-positive

9 (75%)

3 (75%)

Site of disease

 Locoregional

4 (33%)

2 (50%)

 Liver

9 (75%)

4 (100%)

 Bone

8 (67%)

3 (75%)

 Lung

2 (17%)

1 (25%)

 Lymph nodes

3 (25%)

1 (25%)

 CNS

3 (25%)

2 (50%)

 Contralateral breast

0

1 (25%)

 Other

4 (33%)

1 (25%)

Ongoing treatment with trastuzumab

11 (92%)

0

Biopsy post-PET

9 (75%)

3 (75%)

  1. Reprinted from [12]